Lung Cancer Evaluation of TS-1 Study

Lung Cancer Evaluation of TS-1 Study - LETS study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000503

Enrollment

560

Registered

2006-10-18

Start date

2006-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Previously untreated stageIIIB/IV NSCLC

Interventions

CBDCA+TS-1 chemotherapy CBDCA+Paclitaxel chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically or cytologically confirned non-small cell lung cancer (NSCLC) 2)Stage IIIB without any indications for radiotherapy or Stage IV 3)No prior treatment 4)Measurable disease 5)ECOG performance status of 0 or 1 6)More than 20 years old 7)Adequate organ functions 8)Estimated life expectancy of at least 12 weeks 9)Signed informed consent

Exclusion criteria

Exclusion criteria: 1)SVC syndrome 2)Pregnant female or sexually active males/females unwilling to use contraception during the protocol treatment 3)Concomitant serious disease 4)Symptomatic brain metastases 5)Active concomitant malignancy 6)Pleural effusion, cardiac effusion, or cardiac effusion necessiating treatment 7)Uncontrolled diabetes

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026